Clinical Study of Moxifloxacin for Treatment of Community Acquired Pneumonia
Abstract
Objective To valuate the clinical effect and safety of Moxifloxacin for treatment of Community Acquired Pneumonia(CAP).MethodsA randomized method was adopted to compare Moxifloxacin 0.4 g/d(test group)with Cefriaxone Soium 2.0 g/d and Azithromycin 0.5/d(control group)for 106 cases of CAP in Hospitalized Patients from Feb 2008 to Jun 2010.After the treatment of 7~14 days,we observed their clinical effect and safety.ResultsCompared with the total efficiency in test group was significantly higher in control group(90.6% vs 79.2%,P0.05);the time of fever vanishing in test group was significantly shorter than that in control group[(2.64±1.33)d vs(5.39±1.25)d,P0.05];the ratio of bacteria cleared out in test group was significantly higher that in control group(87.5% vs 74.3%,P0.05);test group was similar to control group in the ratio of drug side-effect(5.66% vs 7.55%,P0.05).ConclusionMoxifloxacin has better effect and safety for treatment of CAP,so it may be worth of recommending in clinical experiential use for treatment of CAP.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.